Literature DB >> 26753834

Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor budding in T1 colorectal cancer.

Keita Kai1, Shinichi Aishima1,2, Shigehisa Aoki2, Yukari Takase2, Kazuyoshi Uchihashi2, Masanori Masuda2, Aki Nishijima-Matsunobu2, Mihoko Yamamoto1,2, Kousuke Ide2, Atsushi Nakayama2, Makiko Yamasaki1,2, Shuji Toda2.   

Abstract

Tumor budding is a major risk factor for T1 colorectal cancer. Quality control of the pathological diagnosis of budding is crucial, irrespective of the pathologist's experience. This study examines the interobserver variability according to pathologists' experience and evaluates the influence of cytokeratin (CK) immunostaining in the assessment of budding. Hematoxylin-eosin (HE) and CK-immunostained slides of 40 cases with T1 primary colorectal cancer were examined. Budding grades were individually evaluated by 12 pathologists who we categorized into three groups by their experience (expert, with >10 years of experience (n = 4), senior, with 5-10 years (n = 4), and junior, < 5 years (n = 4)). The results revealed a tendency for the more experienced pathologists to assign higher budding grades compared to the less-experienced pathologists. In the junior group, the interobserver variability obtained with HE slides was poor, but it was markedly improved in the evaluation using CK-immunostained slides. The benefit of CK immunostaining was only slight in the expert group. CK immunostaining would be useful when a pathologist is not experienced enough or does not have enough confidence in the assessment of budding.
© 2016 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  budding; colorectal cancer; cytokeratin; interobserver variability; pathological diagnosis

Mesh:

Substances:

Year:  2016        PMID: 26753834     DOI: 10.1111/pin.12374

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  21 in total

1.  Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

Authors:  Benedikt Martin; Eva Schäfer; Elzbieta Jakubowicz; Patrick Mayr; Regina Ihringer; Matthias Anthuber; Gerhard Schenkirsch; Tina Schaller; Bruno Märkl
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

Review 2.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Authors:  Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean-François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

3.  Prediction of tumor budding in patients with rectal adenocarcinoma using b-value threshold map.

Authors:  Fangying Chen; Shaoting Zhang; Xiaolu Ma; Yukun Chen; Zhen Wang; Yan Zhu; Chenguang Bai; Caixia Fu; Robert Grimm; Chengwei Shao; Jianping Lu; Fu Shen; Luguang Chen
Journal:  Eur Radiol       Date:  2022-08-23       Impact factor: 7.034

4.  Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study.

Authors:  Eva Karamitopoulou; Irene Esposito; Inti Zlobec; Andrea Cacciato Insilla; Martin Wartenberg; David F Schaeffer; Steve Kalloger; Stefano La Rosa; Christine Sempoux; Irene Ramos Centeno; Philipp Lohneis
Journal:  Virchows Arch       Date:  2020-12-17       Impact factor: 4.064

Review 5.  Tumor Budding: The Name is EMT. Partial EMT.

Authors:  Alexandru Dan Grigore; Mohit Kumar Jolly; Dongya Jia; Mary C Farach-Carson; Herbert Levine
Journal:  J Clin Med       Date:  2016-04-29       Impact factor: 4.241

6.  Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma.

Authors:  Nan Xie; Cheng Wang; Zehang Zhuang; Jinson Hou; Xiqiang Liu; Yue Wu; Haichao Liu; Hongzhang Huang
Journal:  Oncotarget       Date:  2016-10-04

Review 7.  Tumour budding and its clinical implications in gastrointestinal cancers.

Authors:  Inti Zlobec; Martin D Berger; Alessandro Lugli
Journal:  Br J Cancer       Date:  2020-06-30       Impact factor: 7.640

Review 8.  Tumour budding in rectal cancer. A comprehensive review.

Authors:  Leonardo S Lino-Silva; Rosa A Salcedo-Hernández; Armando Gamboa-Domínguez
Journal:  Contemp Oncol (Pozn)       Date:  2018-06-30

9.  The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  Hester C van Wyk; James H Park; Joanne Edwards; Paul G Horgan; Donald C McMillan; James J Going
Journal:  Br J Cancer       Date:  2016-06-14       Impact factor: 7.640

10.  Heterogeneous expression of Lgr5 as a risk factor for focal invasion and distant metastasis of colorectal carcinoma.

Authors:  Zhong Zheng; Huiping Yu; Qin Huang; Hongyan Wu; Yao Fu; Jiong Shi; Ting Wang; Xiangshan Fan
Journal:  Oncotarget       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.